A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Biomarkers to predict response to therapy in adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) are not yet established. In this study, we performed a meta-analysis of earlier genome-wide gene expression studies to identify pathway-based genes that are associated with therapeutic response. The predictive power of these genes was validated by transcript profiling in diagnostic bone marrow samples from Ph+ ALL patients using a quantitative real-time PCR array. Gene expression was correlated with cytogenetic and molecular characteristics, including presence of ABL1 mutations and IKZF1 deletion. A total of 43 de novo Ph+ ALL patients treated uniformly with tyrosine kinase inhibitors combined with chemotherapy were selected to validate 46 identified genes. A 9-gene signature was established to distinguish optimal responders from patients with persistent residual disease and early molecular recurrence. The signature was subsequently validated with 87% predictive accuracy in an independent validation set of patients. When initially optimal responders relapsed, their gene expression patterns also shifted. Optimal responders showed upregulation of genes involved in proliferation and apoptosis pathways, whereas poor responders had higher expression of genes that facilitate tumor cell survival in hypoxic conditions as well as development of drug resistance. This unique 9-gene signature may better enable stratification of patients to proper therapeutic regimens and provides new insights into mechanisms of Ph+ ALL response to therapy.

[1]  A. Cherry,et al.  Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. , 2005, Blood.

[2]  T. Naoe,et al.  Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy , 2008, Haematologica.

[3]  B. Druker,et al.  Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib , 2006, Molecular and Cellular Biology.

[4]  M. Relling,et al.  Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. , 2005, Cancer cell.

[5]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[6]  M. Tallman,et al.  Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. , 2009, Blood.

[7]  H. Gschaidmeier,et al.  Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). , 2003, Blood.

[8]  R. Foà,et al.  IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Kantarjian,et al.  Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. , 2008, Blood.

[10]  H. Kantarjian,et al.  Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. , 2007, Blood.

[11]  S. Raimondi,et al.  Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. , 1999, Blood.

[12]  Steven M Kornblau,et al.  Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. , 2004, Blood.

[13]  H. Kantarjian,et al.  Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Cheng Cheng,et al.  Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. , 2004, The New England journal of medicine.

[15]  Yusuke Nakamura,et al.  Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. , 2007, International journal of oncology.

[16]  T. Barrette,et al.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. , 2007, Neoplasia.

[17]  M. Slovak,et al.  Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. , 2008, Blood.

[18]  T. Lipp,et al.  Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. , 2004, Blood.

[19]  R. Foà,et al.  The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial. , 2006, Haematologica.

[20]  T. Naoe,et al.  High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Downing,et al.  Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions , 2009, Leukemia.

[22]  J. Cigudosa,et al.  Genetic and Epigenetic Silencing of microRNA-203 Enhances ABL 1 and BCR-ABL 1 Oncogene Expression , 2008 .

[23]  J. Downing,et al.  Satelite Symposium V, Meet-the-Professor Sessions I and II, Main Sessions I-IX , 2004, Annals of Hematology.

[24]  Kevin R Coombes,et al.  Validation of oligonucleotide microarray data using microfluidic low-density arrays: a new statistical method to normalize real-time RT-PCR data. , 2005, BioTechniques.

[25]  Jill P. Mesirov,et al.  Comparative gene marker selection suite , 2006, Bioinform..

[26]  J. Hay,et al.  A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia , 2007, Expert opinion on pharmacotherapy.

[27]  J. Oldenburg,et al.  Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). , 2007, Blood.

[28]  J. Melo,et al.  The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib , 2006, Leukemia.

[29]  H. Kantarjian,et al.  Kinase domain point mutations in Philadelphia chromosome‐positive acute lymphoblastic leukemia emerge after therapy with BCR‐ABL kinase inhibitors , 2008, Cancer.

[30]  Cheng Cheng,et al.  In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile , 2008, PLoS medicine.

[31]  J. Downing,et al.  A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. , 2007, Blood.

[32]  J. Downing,et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.

[33]  R. Arceci.  Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia , 2010 .

[34]  L. Medeiros,et al.  TaqMan reverse transcriptase-polymerase chain reaction coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. , 2006, Methods in molecular biology.

[35]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[36]  J. Esteve,et al.  Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial , 2010, Haematologica.

[37]  Christopher B. Miller,et al.  BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros , 2008, Nature.

[38]  Ching-Hon Pui,et al.  Acute lymphoblastic leukemia. , 2004, The New England journal of medicine.

[39]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[40]  M. Tallman,et al.  In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin , 2006, Blood.